Longeveron elects Deborah Ascheim to board of directors
LGVN•Pipeline context
The board addition comes as Longeveron advances laromestrocel, with hypoplastic left heart syndrome flagged as its most near-term catalyst.
Board appointment
Longeveron elected Deborah D. Ascheim, M.D. to its board of directors on July 23, 2026.
Ascheim is fractional chief medical officer at Rejuvenate Bio. She previously served as chief medical officer at StrideBio and Capricor Therapeutics, and was founder-president of d2a Ltd., an independent biotech development consultancy.
